Topics
atrial fibrillationDisease
warfarinChemical substance
anticoagulantDrug
MarkovElection
WarfarinChemical substance
rivaroxabanChemical substance
The Author(s) 2013. This article is published with open access at Springerlink.com Background Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advan-tages over warfarin, the standard of care in a world without NOACs, has been introduced and is now recommended by international guidelines. Objective The aim of this study was to evaluate, from a Belgian healthcare payer perspective, the cost-effectiveness of rivaroxaban versus use of warfarin for the treatment of patients with non-valvular AF at moderate to high risk. Met...
Purpose: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in ...
BACKGROUND AND OBJECTIVE: Non-valvular atrial fibrillation (NVAF) increases the risk of systemic th...
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international...
BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been ...
Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives Our ob...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
OBJECTIVE: The aim of this study was to assess the cost effectiveness of the novel fixed-dose antico...
Objective The aim of this study was to assess the cost effectiveness of the novel fixed-dose anticoa...
Objective: The primary objective of this study was to estimate the long-term cost-effectiveness of s...
Background: Management of non-valvular atrial fibrillation (NVAF) focuses on the use of anticoagulat...
OBJECTIVES: Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and ...
OBJECTIVE:The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitam...
Background and Objective: Management of non-valvular atrial fibrillation (NVAF) focuses on the use o...
Purpose: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in ...
BACKGROUND AND OBJECTIVE: Non-valvular atrial fibrillation (NVAF) increases the risk of systemic th...
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international...
BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been ...
Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives Our ob...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
OBJECTIVE: The aim of this study was to assess the cost effectiveness of the novel fixed-dose antico...
Objective The aim of this study was to assess the cost effectiveness of the novel fixed-dose anticoa...
Objective: The primary objective of this study was to estimate the long-term cost-effectiveness of s...
Background: Management of non-valvular atrial fibrillation (NVAF) focuses on the use of anticoagulat...
OBJECTIVES: Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and ...
OBJECTIVE:The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitam...
Background and Objective: Management of non-valvular atrial fibrillation (NVAF) focuses on the use o...
Purpose: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in ...
BACKGROUND AND OBJECTIVE: Non-valvular atrial fibrillation (NVAF) increases the risk of systemic th...
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international...
Add to ORKG